Skip to content

PortoSinusoidal Vascular Diseases and Systemic Sclerosis

PortoSinusoidal Vascular Diseases and Systemic Sclerosis

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06032754
Enrollment
180
Registered
2023-09-13
Start date
2023-02-01
Completion date
2024-03-29
Last updated
2024-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PSVD With or Without SSc

Keywords

Porto-Sinusoidal Vascular Disease, Nodular regenerative hyperplasia, Systemic sclerosis

Brief summary

Porto-Sinusoidal Vascular Disorders (PSVD) is a heterogeneous clinico-pathological entity characterized by alterations in small liver vessels. Nodular regenerative hyperplasia (NRH) is the most common PSVD. The most frequent liver disease associated with Systemic sclerosis (SSc) is primary biliary cholangitis reported in 2 to 22% of cases. NRH prevalence estimated to 1.4%, may be underestimated as NRH diagnosis is histologic and usually suspected in case of complications due to portal hypertension. Few data are available about NRH associated with SSc resulting in a lack of knowledge of the characteristics and outcome of these patients.

Detailed description

The study aims to compare the outcome of patients with MVPS associated with SSc to patients with MVPS without SSc. This work is a multicenter retrospective study comparing two groups of adult patients, one with MVPS associated with SSc and the other with MVPS without SSc. Patients with MVPS associated with SSc will be recruited from French university hospital departments of Hepatogastroenterology and Internal Medecine. Patients with MVPS without SSc will be recruited from the Beaujon Hospital database dedicated to liver vascular diseases.

Interventions

None listed

Sponsors

University Hospital, Caen
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* PSVD (Valdig criteria) * SSC (ACR/EULAR 2013 criteria)

Exclusion criteria

* Liver cirrhosis * Limited scleroderma * Autoimmune hepatitis * Primary biliary cholangitis

Design outcomes

Primary

MeasureTime frameDescription
Prognosis2 yearsTo compare prognosis of PSVD patients with or without SSc (less or more gastrointestinal bleeding/portal vein thrombosis)

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026